National Bank of Canada FI Has $46,000 Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

National Bank of Canada FI raised its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 35.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 848 shares of the company’s stock after buying an additional 220 shares during the period. National Bank of Canada FI’s holdings in CRISPR Therapeutics were worth $46,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Nordea Investment Management AB grew its position in shares of CRISPR Therapeutics by 40.8% during the 1st quarter. Nordea Investment Management AB now owns 148,700 shares of the company’s stock worth $10,305,000 after buying an additional 43,100 shares during the period. Congress Asset Management Co. MA grew its position in shares of CRISPR Therapeutics by 60.3% during the 1st quarter. Congress Asset Management Co. MA now owns 64,605 shares of the company’s stock worth $4,403,000 after buying an additional 24,303 shares during the period. PBCay One RSC Ltd acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at approximately $10,329,000. Cetera Investment Advisers boosted its stake in CRISPR Therapeutics by 451.3% during the 1st quarter. Cetera Investment Advisers now owns 34,100 shares of the company’s stock worth $2,324,000 after acquiring an additional 27,915 shares during the last quarter. Finally, CWM LLC grew its holdings in CRISPR Therapeutics by 11,871.1% during the second quarter. CWM LLC now owns 22,386 shares of the company’s stock valued at $1,209,000 after purchasing an additional 22,199 shares during the period. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock opened at $48.94 on Monday. CRISPR Therapeutics AG has a fifty-two week low of $37.55 and a fifty-two week high of $91.10. The stock has a market cap of $4.16 billion, a P/E ratio of -17.99 and a beta of 1.68. The firm’s fifty day moving average price is $51.12 and its 200-day moving average price is $58.21.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The business had revenue of $0.52 million for the quarter, compared to analyst estimates of $12.31 million. CRISPR Therapeutics’s revenue was down 99.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.98) EPS. Sell-side analysts predict that CRISPR Therapeutics AG will post -5.6 earnings per share for the current year.

Insider Transactions at CRISPR Therapeutics

In other news, COO Julianne Bruno sold 3,366 shares of CRISPR Therapeutics stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $56.09, for a total value of $188,798.94. Following the transaction, the chief operating officer now owns 6,745 shares in the company, valued at $378,327.05. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 4.10% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on the company. Barclays dropped their price objective on CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 6th. Needham & Company LLC decreased their price objective on CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Rodman & Renshaw started coverage on shares of CRISPR Therapeutics in a report on Friday, August 2nd. They set a “buy” rating and a $90.00 target price on the stock. Piper Sandler reiterated an “overweight” rating and issued a $105.00 price target on shares of CRISPR Therapeutics in a report on Monday, June 17th. Finally, Guggenheim restated a “neutral” rating on shares of CRISPR Therapeutics in a report on Friday, June 28th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $75.63.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.